ERBB2 and breast carcinoma: In in vitro studies [119], sensitivity of breast cancer cells to the anti-human ErbB2 (HER2) monoclonal antibody, trastuzumab, was associated with the availability of HS on the cell surface and with the ability of HS to elicit the antibody response by forming a ternary complex with trastuzumab and HER2.